Search Videos by Topic or Participant
Browse by Series:

Novel Agents and Chemotherapy Regimens in PTCL

Panelists: Myron S. Czuczman, MD, Roswell Park; Steve M. Horwitz, MD, MSKCC;Lauren C. Pinter-Brown, MD, UCLA; Andrei R. Shustov, MD, SCCA; Anas
Published: Thursday, Aug 14, 2014
For High-Definition, Click
Novel agents and chemotherapy regimens are currently under exploration in early phase clinical trials for patients with peripheral T-cell lymphoma (PTCL). At this point, chemotherapy regimens with etoposide are the main focus, rather than Adriamycin, explains Myron Czuczman, MD.

Promising findings were demonstrated for romidepsin in a study in patients with PTCL over the age of 60. However, only 30% of the patients were above 70 years old, raising the question of the treatments efficacy in elderly patients, states Andrei R. Shustov, MD.

Studies are also exploring treatment with brentuximab vedotin in patients with PTCL and anaplastic large cell lymphoma (ALCL). These agents are being explored across of variety of settings.

As chemotherapy and novel agents continue to be explored, the next question facing the treatment of lymphoid malignancies will be maintenance therapy, and the optimal duration of treatment, suggests Czuczman.
Slider Left
Slider Right
For High-Definition, Click
Novel agents and chemotherapy regimens are currently under exploration in early phase clinical trials for patients with peripheral T-cell lymphoma (PTCL). At this point, chemotherapy regimens with etoposide are the main focus, rather than Adriamycin, explains Myron Czuczman, MD.

Promising findings were demonstrated for romidepsin in a study in patients with PTCL over the age of 60. However, only 30% of the patients were above 70 years old, raising the question of the treatments efficacy in elderly patients, states Andrei R. Shustov, MD.

Studies are also exploring treatment with brentuximab vedotin in patients with PTCL and anaplastic large cell lymphoma (ALCL). These agents are being explored across of variety of settings.

As chemotherapy and novel agents continue to be explored, the next question facing the treatment of lymphoid malignancies will be maintenance therapy, and the optimal duration of treatment, suggests Czuczman.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x